FDA Requires New Vision-Loss Risk Warnings for All GLP-1 Class Drugs

New warnings for the entire class of drugs

The U.S. Food and Drug Administration (FDA) announced on Mondaythat weight-loss drugs are linked to the development of non-arteritic anterior ischemic optic neuropathy (NAION) — a condition that can cause sudden, painless vision loss in one eye, including permanent loss. Euronews reports on this.

Who the decision affects and what it is based on

The new warning requirements apply to all GLP-1 receptor agonists — a class of drugs widely used for type 2 diabetes and obesity. It includes Ozempic and Wegovy from Novo Nordisk, Mounjaro and Zepbound from Eli Lilly, and other drugs. The FDA's assessment included an analysis of 126 clinical trials involving more than 134,000 patients; the regulator also reviewed real-world clinical practice data and published observational studies. Acknowledging the limitations of the available evidence, the agency concluded that the potentially increased risk warrants additional warnings for the entire class. In practical terms, this means that information about the risk will appear in the labeling for all drugs in the class, not just individual products.

How this differs from the European regulator's position

The FDA's decision heightens attention to the safety of a rapidly expanding class of drugs that have become key in treating obesity and type 2 diabetes. Earlier, the European Medicines Agency (EMA) recognized NAION as a very rare side effect of semaglutide — the active ingredient in a number of weight-loss drugs — which may affect up to one patient in 10,000. Thus, the FDA extended the warning to the entire GLP-1 class, whereas the European conclusion concerned semaglutide specifically and assessed the condition's frequency as very rare.